These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 23976947)

  • 41. Directed selection of influenza virus produces antigenic variants that match circulating human virus isolates and escape from vaccine-mediated immune protection.
    DeDiego ML; Anderson CS; Yang H; Holden-Wiltse J; Fitzgerald T; Treanor JJ; Topham DJ
    Immunology; 2016 Jun; 148(2):160-73. PubMed ID: 26854888
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Characterization of influenza vaccine immunogenicity using influenza antigen microarrays.
    Price JV; Jarrell JA; Furman D; Kattah NH; Newell E; Dekker CL; Davis MM; Utz PJ
    PLoS One; 2013; 8(5):e64555. PubMed ID: 23734205
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Convergent antibody evolution and clonotype expansion following influenza virus vaccination.
    Forgacs D; Abreu RB; Sautto GA; Kirchenbaum GA; Drabek E; Williamson KS; Kim D; Emerling DE; Ross TM
    PLoS One; 2021; 16(2):e0247253. PubMed ID: 33617543
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Influenza Vaccine-Induced Antibody Responses Are Not Impaired by Frailty in the Community-Dwelling Elderly With Natural Influenza Exposure.
    Narang V; Lu Y; Tan C; Camous XFN; Nyunt SZ; Carre C; Mok EWH; Wong G; Maurer-Stroh S; Abel B; Burdin N; Poidinger M; Tambyah PA; Bosco N; Visan L; Ng TP; Larbi A
    Front Immunol; 2018; 9():2465. PubMed ID: 30405641
    [No Abstract]   [Full Text] [Related]  

  • 45. Novel influenza vaccine M2SR protects against drifted H1N1 and H3N2 influenza virus challenge in ferrets with pre-existing immunity.
    Hatta Y; Boltz D; Sarawar S; Kawaoka Y; Neumann G; Bilsel P
    Vaccine; 2018 Aug; 36(33):5097-5103. PubMed ID: 30007825
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Heads, stalks and everything else: how can antibodies eradicate influenza as a human disease?
    Neu KE; Henry Dunand CJ; Wilson PC
    Curr Opin Immunol; 2016 Oct; 42():48-55. PubMed ID: 27268395
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pre-existing immunity to influenza virus hemagglutinin stalk might drive selection for antibody-escape mutant viruses in a human challenge model.
    Park JK; Xiao Y; Ramuta MD; Rosas LA; Fong S; Matthews AM; Freeman AD; Gouzoulis MA; Batchenkova NA; Yang X; Scherler K; Qi L; Reed S; Athota R; Czajkowski L; Han A; Morens DM; Walters KA; Memoli MJ; Kash JC; Taubenberger JK
    Nat Med; 2020 Aug; 26(8):1240-1246. PubMed ID: 32601336
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Neutralizing antibody but not hemagglutination antibody provides accurate evaluation for protective immune response to H5N1 avian influenza virus in vaccinated rabbits.
    Zhu H; Ding X; Chen X; Yao P; Xu F; Xie R; Yang Z; Liang W; Zhang Y; Li Y; Shen J; He P; Guo Z; Su B; Sun S; Zhu Z
    Vaccine; 2011 Jul; 29(33):5421-3. PubMed ID: 21645575
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Single-replication BM2SR vaccine provides sterilizing immunity and cross-lineage influenza B virus protection in mice.
    Moser MJ; Hatta Y; Gabaglia C; Sanchez A; Dias P; Sarawar S; Kawaoka Y; Hatta M; Neumann G; Bilsel P
    Vaccine; 2019 Jul; 37(32):4533-4542. PubMed ID: 31280945
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge.
    Mooney AJ; Gabbard JD; Li Z; Dlugolenski DA; Johnson SK; Tripp RA; He B; Tompkins SM
    J Virol; 2017 Dec; 91(23):. PubMed ID: 28931689
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Development and characterization of a panel of cross-reactive monoclonal antibodies generated using H1N1 influenza virus.
    Guo CY; Tang YG; Qi ZL; Liu Y; Zhao XR; Huo XP; Li Y; Feng Q; Zhao PH; Wang X; Li Y; Wang HF; Hu J; Zhang XJ
    Immunobiology; 2015 Aug; 220(8):941-6. PubMed ID: 25708705
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Discordant antigenic drift of neuraminidase and hemagglutinin in H1N1 and H3N2 influenza viruses.
    Sandbulte MR; Westgeest KB; Gao J; Xu X; Klimov AI; Russell CA; Burke DF; Smith DJ; Fouchier RA; Eichelberger MC
    Proc Natl Acad Sci U S A; 2011 Dec; 108(51):20748-53. PubMed ID: 22143798
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Unmasking Stem-Specific Neutralizing Epitopes by Abolishing N-Linked Glycosylation Sites of Influenza Virus Hemagglutinin Proteins for Vaccine Design.
    Liu WC; Jan JT; Huang YJ; Chen TH; Wu SC
    J Virol; 2016 Oct; 90(19):8496-508. PubMed ID: 27440889
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cell-Mediated Immunity Against Antigenically Drifted Influenza A(H3N2) Viruses in Children During a Vaccine Mismatch Season.
    Kim JH; Mishina M; Chung JR; Cole KS; Nowalk MP; Martin JM; Spencer S; Flannery B; Zimmerman RK; Sambhara S
    J Infect Dis; 2016 Oct; 214(7):1030-8. PubMed ID: 27534687
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of the immunogenicity and protective effects of a trivalent chimeric norovirus P particle immunogen displaying influenza HA2 from subtypes H1, H3 and B.
    Gong X; Yin H; Shi Y; He X; Yu Y; Guan S; Kuai Z; Haji NM; Haji NM; Kong W; Shan Y
    Emerg Microbes Infect; 2016 May; 5(5):e51. PubMed ID: 27222326
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies.
    Krammer F; Pica N; Hai R; Margine I; Palese P
    J Virol; 2013 Jun; 87(12):6542-50. PubMed ID: 23576508
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Globular Head-Displayed Conserved Influenza H1 Hemagglutinin Stalk Epitopes Confer Protection against Heterologous H1N1 Virus.
    Klausberger M; Tscheliessnig R; Neff S; Nachbagauer R; Wohlbold TJ; Wilde M; Palmberger D; Krammer F; Jungbauer A; Grabherr R
    PLoS One; 2016; 11(4):e0153579. PubMed ID: 27088239
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Neutralizing and protective epitopes of the 2009 pandemic influenza H1N1 hemagglutinin.
    Schmeisser F; Friedman R; Besho J; Lugovtsev V; Soto J; Wang W; Weiss C; Williams O; Xie H; Ye Z; Weir JP
    Influenza Other Respir Viruses; 2013 May; 7(3):480-90. PubMed ID: 23122228
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Broadly Cross-Reactive, Nonneutralizing Antibodies against Influenza B Virus Hemagglutinin Demonstrate Effector Function-Dependent Protection against Lethal Viral Challenge in Mice.
    Asthagiri Arunkumar G; Ioannou A; Wohlbold TJ; Meade P; Aslam S; Amanat F; Ayllon J; García-Sastre A; Krammer F
    J Virol; 2019 Mar; 93(6):. PubMed ID: 30626682
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A Computationally Optimized Broadly Reactive Antigen Subtype-Specific Influenza Vaccine Strategy Elicits Unique Potent Broadly Neutralizing Antibodies against Hemagglutinin.
    Sautto GA; Kirchenbaum GA; Abreu RB; Ecker JW; Pierce SR; Kleanthous H; Ross TM
    J Immunol; 2020 Jan; 204(2):375-385. PubMed ID: 31811019
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.